YSPH Statement Regarding Hydroxychloroquine
Dr. Harvey Risch is a distinguished cancer epidemiologist who has opined on the topic of hydroxychloroquine (HCQ) and COVID-19 out-patient therapy. He has written a review article in the American Journal of Epidemiology that cites evidence that he believes supports HCQ use for out-patient infection with SARS-CoV-2. Studies that indicate no effect or harmful effects, Dr. Risch believes, enrolled patients too sick to benefit from HCQ.
What COVID-19 is Teaching Us About Humanitarian Responses: Part I
6.25.20 “COVID-19 Right Now” featuring Kaveh Khoshnood, PhD, MPH, Associate Professor of Epidemiology and Program Co-Director for the Global Ethics Program at the Yale Institute of Global Health; and James Hamblin, MD, MPH, Lecturer in Health Policy and Management
A Look at Russia’s Response to the Coronavirus
6.18.20 “COVID-19 Right Now” featuring Robert Heimer, PhD, Professor of Epidemiology of Microbial Diseases; Judyth Twigg, PhD, professor of political science, Virginia Commonwealth University; and James Hamblin, MD, MPH, Lecturer, Health Policy and Management.
Public Health Professor Plays Key Role as Connecticut Recovers from Pandemic
To Connecticut Gov. Ned Lamont, Yale School of Public Health Professor Albert Ko is “our Dr. Fauci.” Much like the actual Dr. Tony Fauci, director of National Institute of Allergy and Infectious Diseases and a familiar national presence throughout the pandemic, Ko takes the ongoing fight against COVID-19 extremely seriously. Though cases are in decline since rates of disease peaked in late April, and the state is seeing a decrease of hospitalizations and deaths, to Ko, the fight has just begun.
Strong Public Health Response in China Slowed Coronavirus Transmission, YSPH Study Finds
Swift isolation and quarantine policies as well as city lockdowns imposed by the Chinese government in late January 2020 significantly decreased the transmission rate of COVID-19, new research led by the Yale School of Public Health finds.